672 results on '"Lacouture, Mario E."'
Search Results
2. Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique
3. Predictors of immediate and delayed cutaneous hypersensitivity reactions to paclitaxel
4. Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)
5. Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients
6. CSF1R inhibition for histiocytic neoplasm with CBL mutations refractory to MEK1/2 inhibition
7. PRO-CTCAE reveals under-recognition of dermatologic symptom burden in hospitalized cancer patients
8. Phase 1/2 study of topical submicron particle paclitaxel for cutaneous metastases of breast cancer
9. Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis
10. Oncodermatology: Advancing the Science and Care of Cancer Patients and Survivors
11. A multidisciplinary approach to optimizing care of patients treated with alpelisib
12. Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management
13. Dermatologic infections in cancer patients treated with checkpoint inhibitors
14. Restorative oncodermatology: Diagnosis and management of dermatologic sequelae from cancer therapies
15. Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy
16. Immune-related cutaneous adverse events due to checkpoint inhibitors
17. Association of interleukin-6 and tumor necrosis factor-α with mortality in hospitalized patients with cancer
18. Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy.
19. Immune checkpoint inhibitors to treat cutaneous malignancies
20. Immune checkpoint inhibitor–related dermatologic adverse events
21. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features
22. SJS/TEN 2019: From science to translation
23. A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia
24. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors
25. Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer
26. Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
27. Randomized controlled trial of cryotherapy to prevent paclitaxel-induced peripheral neuropathy (RU221511I); an ACCRU trial
28. Drugs as a Frequent Cause of Acute Rash in Patients after CD34+-Selected Peripheral Blood Stem Cell Transplantation
29. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study
30. Hair disorders in patients with cancer
31. Hair disorders in cancer survivors
32. Markers of systemic involvement and death in hospitalized cancer patients with severe cutaneous adverse reactions
33. Li-Fraumeni Syndrome-related Malignancies Involving the Genitourinary Tract: Review of a Single-institution Experience
34. Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review
35. Inflammatory dermatoses, infections, and drug eruptions are the most common skin conditions in hospitalized cancer patients
36. SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation
37. Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms
38. The effect of scalp cooling on CIA-related quality of life in breast cancer patients: a systematic review
39. Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies
40. Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis
41. Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042)
42. A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013
43. Clinical presentations of skin of color in oncodermatology
44. Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update
45. A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies
46. A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer
47. Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms.
48. IL12/23 Blockade with Ustekinumab as a Treatment for Immune-Related Cutaneous Adverse Events.
49. Incidence and risk of xerosis with targeted anticancer therapies
50. A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.